je.st
news
Tag: novavax
Stoneridge Investment Partners LLC Raises Stake in Novavax, Inc.
2016-03-09 13:59:21| Biotech - Topix.net
Stoneridge Investment Partners LLC raised its stake in Novavax, Inc. by 1.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission . The firm owned 231,352 shares of the biopharmaceutical company's stock after buying an additional 3,721 shares during the period.
Tags: inc
partners
llc
investment
Novavax, Inc. Forecasted to Post FY2020 Earnings of $0.72 Per Share
2016-02-07 12:04:19| Biotech - Topix.net
Research analysts at FBR & Co. issued their FY2020 earnings per share estimates for Novavax in a research note issued to investors on Thursday, according to Zacks Investment Research .
Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023
2016-01-25 13:46:50| Biotech - Topix.net
Novavax, Inc. , a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 . The Notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Tags: due
notes
million
senior
Novavax: Early study indicates its vaccine effective vs. RSV
2015-08-11 03:06:09| Biotech - Topix.net
Early research in older adults found an experimental vaccine prevented nearly two-thirds of serious cases of a common, seasonal respiratory virus that annually kills thousands of vulnerable Americans - babies and senior citizens. If further testing by vaccine developer Novavax Inc. goes well, in a few years the biotech company's genetically engineered shot could become the first vaccine approved against respiratory syncytial virus, or RSV.
Tags: study
early
effective
vs
Novavax: Early study indicates its vaccine effective vs. RSV
2015-08-11 03:06:08| Biotech - Topix.net
Early research in older adults found an experimental vaccine prevented nearly two-thirds of serious cases of a common, seasonal respiratory virus that annually kills thousands of vulnerable people - babies and senior citizens. If further testing by vaccine developer Novavax Inc. goes well, in a few years the biotech company's genetically engineered shot could become the first vaccine approved against respiratory syncytial virus, or RSV.
Tags: study
early
effective
vs